FDA approves skin cancer vaccine by...?

The central question is whether intismeran autogene, the personalized mRNA neoantigen therapy from Moderna and Merck, receives any FDA approval by December 31, 2027. The latest context points to a strong clinical signal from phase 3 development, which is the main reason the market is above 50 percent. A positive phase 3 readout would materially improve the odds of approval, especially because the market definition allows approval for any indication, any narrower population, and even accelerated approval if the FDA is satisfied with the package. That said, a positive trial result is not equivalent to an approvable regulatory package, and this category of therapy is still relatively novel for the FDA.

The biggest reason to stay cautious is that no actual FDA approval has occurred yet, and the remaining path is not trivial. Personalized cancer vaccines create additional complexity because the product is not a standard off-the-shelf biologic, but a platform that depends on individualized manufacturing, quality control, turnaround time, and consistency across patients. Even if the clinical benefit is promising, the FDA may still scrutinize CMC issues, assay validation, dose consistency, and the link between the manufacturing process and the final product. Those issues often matter more for a first-in-class platform than for a conventional oncology drug, and they can delay approval even when efficacy data look good.

Historical precedent also cuts both ways. The FDA has approved very few therapeutic cancer vaccines overall, which means there is not a deep precedent for this exact regulatory path in skin cancer. On the other hand, the agency has shown willingness to approve innovative oncology therapies when the benefit-risk profile is strong and the unmet need is real. Melanoma is a high-profile indication with meaningful unmet need in some settings, so if phase 3 data remain favorable and the sponsor executes cleanly, approval before 2028 is realistic. Still, with more than a year left, the market likely prices in a successful development trajectory that is not yet fully de-risked.

Relative to the current price of 67.5 percent, my estimate is lower because the market appears to be giving substantial credit to the positive trial result and the credibility of the sponsor combination. I agree the probability is above coin-flip territory, but I do not think the evidence justifies nearly a two-in-three chance yet. The most important uncertainty is not whether the program has promise, but whether the full regulatory package, manufacturing readiness, and final FDA review can all align on time.